Pritelivir

Pritelivir is a novel therapeutic agent being developed to address a critical unmet need in the management of herpes simplex virus infections. As a helicase-primase inhibitor, Pritelivir offers a new mechanism of action that is effective against HSV strains that have developed resistance to standard nucleoside analogue therapies . In clinical trials, Pritelivir has demonstrated superior efficacy compared to investigator's choice therapy for immunocompromised patients, achieving significantly higher rates of complete lesion healing . The favourable safety profile and oral bioavailability of Pritelivir make it a convenient and well-tolerated option for patients, potentially transforming the standard of care . Beyond its clinical potential, Pritelivir serves as a critical reference standard in drug development and analytical research for HSV therapeutics.

Product Parameters

Bioactivity

Pritelivir (BAY 57-1293, AIC316) is a potent helicase-primase inhibitor with antiviral activity against both herpes simplex virus (HSV)-1 and HSV-2, exhibiting an IC₅₀ value of 20 nM.

In vitro study

The mechanism of action involves BAY57-1293 directly inhibiting the ATPase activity of the viral helicase–primase complex in a dose-dependent manner. BAY57-1293 also exhibits potent antiviral activity against acyclovir-resistant HSV mutants. Furthermore, BAY57-1293 reduces the production of Aβ and P-tau induced by type 1 herpes simplex virus in Vero cells.

In vivo studies

BAY57-1293 (oral administration) demonstrated potent antiviral activity in lethal disseminated herpes infection models in mice and rats (0.5 mg/kg), in a shingles-like skin disease dissemination model in mice (15 mg/kg), and in an ocular herpes model in mice.

Contact Us

Whether you are conducting antiviral drug discovery research, developing analytical methods for HSV therapeutics, or studying resistance mechanisms, Cosperpharm is your trusted partner for high-quality Pritelivir. Contact us today to discuss your requirements.